^
Association details:
| Biomarker: | ER mutation |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | fulvestrant (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Published date:
06/16/2020
Excerpt:
ESR1 mutations were detected in 30% (151/383) baseline samples. In patients with ESR1 mutation detected, PFS was 2.4 months (95%CI,2.0-2.6) on exemestane and 3.9 months (95%CI,3.0-6.0) on fulvestrant (HR=0.59, 95%CI,0.39-0.89; p=0.01). Patients with ESR1 mutation detected had one-year overall survival of 62% (95%CI,45%-75%) on exemestane and 80% (95%CI,68%-87%) on fulvestrant (p=0.04, restricted mean survival analysis).
DOI:
10.1158/1078-0432.CCR-20-0224
Source:
Title:
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
Excerpt:
......
Trial ID:
Source:
Title:
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
Excerpt:
...The blood sample is clarified to be ESR1 mutated,...
Trial ID:
